FDA advisory panel recommends monovalent XBB COVID-19 vaccine for fall
The Food and Drug Administration’s vaccine advisory committee June 15 voted unanimously to recommend updating the current COVID-19 vaccine composition for fall to a monovalent vaccine based on an XBB variant of the virus, the lineage currently predominating in the U.S. The FDA will now consider the recommendation.
Related News Articles
Headline
Fewer than one in four health care professionals working in acute care hospitals and nursing homes were up to date with COVID-19 vaccination during the 2022-23…
Headline
Children under age 12 should receive a 0.25 milliliter dose of the 2023-24 Moderna COVID-19 vaccine, not the full vial for that age group, the Food and Drug…
Headline
The Department of Health and Human Services Oct. 27 urged Merck and Pfizer to work with private insurers to maintain access to their COVID-19 oral antiviral…
News
To enjoy a healthy Thanksgiving with family and friends, get vaccinated against the flu and COVID-19. That’s the message of AHA’s latest United Against the Flu…
Headline
The Department of Health and Human Services’ Administration for Strategic Preparedness and Response recently awarded over $500 million to prepare for clinical…
Headline
The Department of Health and Human Services in November will begin transitioning to commercial distribution an estimated 7.9 million treatment courses of the…